Chimerix to Present at JonesTrading Virtual Precision Medicine Symposium

Core Insights - Chimerix, a biopharmaceutical company, focuses on developing medicines to improve and extend the lives of patients with deadly diseases [1][3] - The company will participate in a fireside chat at the JonesTrading Virtual Precision Medicine Symposium on February 3, 2025 [1] - An audio webcast of the discussion will be available on Chimerix's Investor Relations website for approximately 90 days [2] Company Overview - Chimerix's most advanced clinical-stage development program is dordaviprone, aimed at treating H3 K27M-mutant glioma [3] - The company is also conducting Phase 1 dose escalation studies of ONC206 to evaluate safety and pharmacokinetic data [3]